Crinetics Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US22663K1079

Introduction

This page provides a comprehensive analysis of the known insider trading history of Alan Seth Krasner. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Alan Seth Krasner has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CRNX / Crinetics Pharmaceuticals, Inc. Chief Medical Officer 43,210
US:BIOD / Biodel, Inc. Chief Medical Officer 100,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Alan Seth Krasner. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CRNX / Crinetics Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CRNX / Crinetics Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2018-07-20 CRNX Krasner Alan Seth 2,000 17.0000 2,000 17.0000 34,000 54 36.8 39,600 116.47

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CRNX / Crinetics Pharmaceuticals, Inc. Insider Trades
Insider Sales CRNX / Crinetics Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CRNX / Crinetics Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2023-10-17 CRNX Krasner Alan Seth 7,000 30.0000 7,000 30.0000 210,000 23 26.6900 -23,170 -11.03

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CRNX / Crinetics Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Alan Seth Krasner as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2023-10-19 2023-10-17 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock
S - Sale -7,000 43,210 -13.94 30.00 -210,000 1,296,300
2023-10-19 2023-10-17 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock
M - Exercise 7,000 50,210 16.20 12.01 84,070 603,022
2023-03-17 2023-03-16 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock
F - Taxes X -1,687 42,301 -3.84 17.12 -28,881 724,193
2023-03-03 2023-03-01 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock
A - Award 19,500 43,988 79.63
2023-01-27 2022-11-20 5 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock
J - Other 712 24,488 2.99 11.02 7,846 269,858
2023-01-27 2022-05-20 5 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock
J - Other 1,215 23,776 5.39 11.02 13,389 262,012
2022-03-02 2022-02-28 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock (right to buy)
A - Award 66,500 66,500
2022-03-02 2022-02-28 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock
A - Award 14,250 22,561 171.46
2022-01-21 2022-01-19 4 CRNX Crinetics Pharmaceuticals, Inc.
Non-qualified stock option (Right to Buy)
M - Exercise X -6,700 160,473 -4.01
2022-01-21 2022-01-19 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock
S - Sale X -6,700 8,311 -44.63 21.21 -142,080 176,243
2022-01-21 2022-01-19 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock
M - Exercise X 6,700 15,011 80.62 12.01 80,467 180,282
2021-03-02 2021-02-26 4 CRNX Crinetics Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 125,000 125,000
2021-02-05 2020-11-20 5 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock
J - Other 277 6,383 4.54 11.61 3,216 74,107
2021-02-05 2020-05-20 5 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock
J - Other 1,165 6,106 23.58 14.45 16,834 88,232
2020-02-26 2020-02-24 4 CRNX Crinetics Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 45,000 45,000
2020-02-11 2019-05-20 5 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock
J - Other 1,471 4,941 42.39 14.45 21,256 71,397
2019-03-12 2019-03-08 4 CRNX Crinetics Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 56,250 56,250
2019-02-12 2018-11-20 5 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock
J - Other 1,470 3,470 73.50 14.45 21,242 50,142
2018-07-20 2018-07-20 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock
P - Purchase 2,000 2,000 17.00 34,000 34,000
2014-12-23 2014-12-19 4 BIOD Biodel Inc
Stock Option (Right to Buy)
A - Award 100,000 100,000
2014-03-14 2014-03-12 4 BIOD Biodel Inc
Restricted Stock Unit
M - Exercise 6,026 0 -100.00
2014-03-14 2014-03-12 4 BIOD Biodel Inc
Common Stock
F - Taxes -1,843 35,687 -4.91
2014-03-14 2014-03-12 4 BIOD Biodel Inc
Common Stock
M - Exercise 6,026 37,530 19.13
2013-12-23 2013-12-23 4 BIOD Biodel Inc
Stock Option (Right to Buy)
A - Award 105,000 105,000
2013-03-14 2013-03-12 4 BIOD Biodel Inc
Restricted Stock Unit
M - Exercise 6,024 6,026 301,200.00
2013-03-14 2013-03-12 4 BIOD Biodel Inc
Common Stock
F - Taxes -1,854 31,504 -5.56
2013-03-14 2013-03-12 4 BIOD Biodel Inc
Common Stock
M - Exercise 6,024 33,358 22.04
2012-12-21 2012-12-21 4 BIOD Biodel Inc
Stock Option (Right to Buy)
A - Award -37,000 37,000 -50.00
2012-11-05 2012-11-02 4 BIOD Biodel Inc
Common Stock
S - Sale X -1,100 27,334 -3.87 2.78 -3,058 75,989
2012-11-05 2012-11-01 4 BIOD Biodel Inc
Common Stock
S - Sale X -2,400 28,434 -7.78 2.82 -6,768 80,184
2012-10-02 2012-09-30 4 BIOD Biodel Inc
Restricted Stock Unit
M - Exercise 27,296 0 -100.00
2012-10-02 2012-09-30 4 BIOD Biodel Inc
Common Stock
F - Taxes -8,323 30,834 -21.26 2.87 -23,887 88,494
2012-10-02 2012-09-30 4 BIOD Biodel Inc
Common Stock
M - Exercise 27,296 39,157 230.13
2012-04-02 2012-03-29 4 BIOD Biodel Inc
Restricted Stock Units
A - Award 109,184 109,184
2012-03-14 2012-03-12 4 BIOD Biodel Inc
Restricted Stock Unit
M - Exercise -35,350 0 -100.00
2012-03-14 2012-03-12 4 BIOD Biodel Inc
Common Stock
M - Exercise 35,350 47,445 292.27
2008-05-29 2008-05-27 4 BIOD Biodel Inc
Common Stock
A - Award 100,000 100,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)